End Stage Renal Disease Economics - Coursework Example

comes were not clear to evaluate due to insignificant increase in the number of physicians and clinics to take care of the ESRD patients all over the country sufficiently. Before then, the discussions concerning the program were treated as options that would keep the cost of providing care low (D., 2010). The current Medicare payment is $20.3 billion and this seems to burden the taxpayers. Comparing the medical expenses on peritoneal dialysis (PD) and the traditional in center hemodialysis; apparently, the End Stage Renal Disease patients will spend less if they are under PD than SERD.

However, despite these economic relief, the United States’ taxpayers, the number of PD patients has remained constant with many patient being prescribed for the in-center hemodialysis treatments ("Baxter announces the launch." 2003). The simple way of reducing the medical expenses on the Stage Renal Disease treatment would be to increase the peritoneal dialysis, as opposed to in- center hemodialysis. Nonetheless, critics hold that these Medicare program initiatives are just but myths. The Renal Disease diseases are often caused by kidney failure.

The end stage renal disease has no cure; thus, patient suffering from this disease can either undertake dialysis or kidney transplantation for their survival. Failure of immediate treatment may lead to uremia, that is, a buildup fluid and toxic substances in the blood ("Baxter announces the launch." 2003). This condition often leads to death after a few days or week of infection. The intense effect of this disease depends on the functions of the existing renal as the kidneys deteriorate. The ideal way of treating the end stage renal disease is through transplantation; however, in the United States, the rate of transplantation has remained low due to lack of the organs (D., 2010). Nonetheless, studies have indicated that patients can also get quality life through therapies.

Additionally, these therapies have proved to be the most